Optum vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Optum leads in AI visibility (93 vs 92)

Optum

LeaderHealthcare

Health Services Tech

UnitedHealth Group (NYSE: UNH) health services at $226B revenue combining Optum Health clinics, Optum Rx PBM for 65M+, and Change Healthcare analytics; largest US health services company competing with CVS/Caremark.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 1
AI Consensus
63%
Trend
stable
Per Platform
ChatGPT
95
Perplexity
99
Gemini
84

About

Optum is the health services subsidiary of UnitedHealth Group (NYSE: UNH) — one of the world's largest companies with $400 billion in annual revenue — operating Optum Health (care delivery: primary care clinics, urgent care, surgical centers), Optum Rx (pharmacy benefit management: managing drug benefits for 65+ million people), and Optum Insight (health data analytics, technology, and consulting for health plans, providers, and government). With $226 billion in annual revenue in its own right (making Optum larger than most standalone health companies), Optum generates approximately 50% of UnitedHealth Group's total revenue and is the largest health services company in the world.

Full profile

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A92
Category Rank
#61 of 1167
AI Consensus
73%
Trend
down
Per Platform
ChatGPT
86
Perplexity
90
Gemini
92

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

93
Overall Score
92
#1
Category Rank
#61
63
AI Consensus
73
stable
Trend
down
95
ChatGPT
86
99
Perplexity
90
84
Gemini
92
95
Claude
98
99
Grok
93

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.